Intravenous Immunoglobulins: Mechanisms of Therapeutic Effects

Лазанович, В. А.; Просекова, Е. В.

doi:10.15789/1563-0625-2014-4-311-322

Cited by 2 publications

(1 citation statement)

References 31 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Показаниями для введения препарата являлись: -острая вирусная инфекция (защита плода); -обострение бактериально-вирусной инфекции у женщин с привычной потерей беременности, с угрозой прерывания, явлениями хориоамнионита, с повышенным количеством nк-клеток и провоспалительных цитокинов в крови; -привычное невынашивание беременности инфекционного генеза (хронический эндо-метрит, истмико-цервикальная недостаточность); -хирургические вмешательства при беременности (зашивание шейки матки, инвазивные методы пренатальной диагностики) [28]. Противопоказанием для введения IVIg служили наличие у пациенток аллергических реакций на препараты крови в анамнезе и иммунодефицит IgA.…”

Section: материалы и методыunclassified

Experience with intravenous immunoglobulin treatment in pregnant women with miscarriage and chronic endometritis

et al. 2018

View full text Add to dashboard Cite

Chronic endometritis is the most common endometrial pathology in women with habitual miscarriage. Urogenital infections, persistence of pathogenic and opportunistic flora lead to chronic inflammatory process in the endometrium and secondary immunodeficiency states. In the endometrium, an increased number of NK- (CD16+ and CD56+), В- (CD20+) lymphocytes and cells expressing the late HLA-DR activation marker are determined. These lymphocytes enhance the expression of histocompatibility antigens by endometrial cells and lead to autoimmune inflammation. The imbalance between immune tolerance to the fetus and immune activation to the pathogenic organisms is associated with poor pregnancy outcomes. After a course of complex therapy of chronic endometritis, most women with miscarriage can only reduce the severity of the inflammatory process in the endometrium. The aim of this study was to assess the importance of immunomodulatory effects of human immunoglobulin during pregnancy in women with miscarriage. The study included 182 patients with a history of miscarriage and chronic endometritis. Group 1 consisted of 98 women who received an intravenous course of human immunoglobulin at 7/8 weeks of pregnancy. Group 2 comprised 84 pregnant women who did not receive immunoglobulin therapy. An analysis of the results of the course and outcomes of pregnancy showed that administering an intravenous immunoglobulin course to pregnant women with miscarriage and chronic endometritis in the history prior to the first wave of trophoblast invasion helps to reduce the frequency of threatened abortion (54% in group 1 and 95% in group 2, p < 0.001). The data obtained suggest that intravenous immunoglobulin should be recommended for women with habitual miscarriage and chronic endometritis during pregnancy up to 8 weeks.

show abstract

Section: материалы и методыunclassified

Experience with intravenous immunoglobulin treatment in pregnant women with miscarriage and chronic endometritis

et al. 2018

View full text Add to dashboard Cite

show abstract

Peculiar features of intravenous immunoglobulins application in rheumatic diseases

Egorova,

Tarasova,

Datsina

et al. 2024

Sovremennaâ revmatologiâ

View full text Add to dashboard Cite

Intravenous immunoglobulins (IVIG) are the most commonly used immunobiological agents produced from donor blood. They were first used in the mid-twentieth century for the treatment of primary immunodeficiencies. Later, they were successfully used to treat a variety of autoimmune, inflammatory and other diseases. There are currently a growing number of basic and clinical studies looking at the mechanism of action and efficacy of different doses of IVIG. At the same time, much remains unclear, contradictory, and some data are mutually exclusive.

show abstract

Intravenous Immunoglobulins: Mechanisms of Therapeutic Effects

Cited by 2 publications

References 31 publications

Experience with intravenous immunoglobulin treatment in pregnant women with miscarriage and chronic endometritis

Experience with intravenous immunoglobulin treatment in pregnant women with miscarriage and chronic endometritis

Peculiar features of intravenous immunoglobulins application in rheumatic diseases

Contact Info

Product

Resources

About